Ewf Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
as on 05-01-2025
- Paid Up Capital ₹ 4.91 M
as on 05-01-2025
- Company Age 25 Year, 9 Months
- Last Filing with ROC 31 Mar 2019
- Open Charges ₹ 2.00 M
as on 05-01-2025
- Revenue %
(FY 2019)
- Profit -801.13%
(FY 2019)
- Ebitda -1470.30%
(FY 2019)
- Net Worth -0.13%
(FY 2019)
- Total Assets -26.43%
(FY 2019)
About Ewf Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2019. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 4.91 M.
The company currently has active open charges totaling ₹2.00 M.
Anuj Saxena, Anshul Saxena, and Santosh Rane serve as directors at the Company.
- CIN/LLPIN
U51397MH1999PTC119261
- Company No.
119261
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
05 Apr 1999
- Date of AGM
30 Sep 2019
- Date of Balance Sheet
31 Mar 2019
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- LocationMumbai, Maharashtra
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Ewf Pharmaceuticals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Anshul Saxena  | Director | 28-Feb-2018 | Current |
| Anuj Saxena | Director | 04-Dec-2020 | Current |
| Santosh Rane | Additional Director | 10-Feb-2022 | Current |
Financial Performance of Ewf Pharmaceuticals.
Ewf Pharmaceuticals Private Limited, for the financial year ended 2019, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 801.13% decrease in profit. The company's net worth dipped by a decrease of 0.13%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Ewf Pharmaceuticals?
In 2019, Ewf Pharmaceuticals had a promoter holding of 45.03% and a public holding of 54.97%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Limelight Communications Private LimitedActive 15 years 2 monthsAnuj Saxena, Anshul Saxena and 1 more are mutual person
Redle Pharmaceuticals Private LimitedActive 16 years 10 monthsAnuj Saxena, Anshul Saxena and 1 more are mutual person
- Apricot Capitals Private LimitedActive 16 years 10 months
Anuj Saxena, Anshul Saxena and 1 more are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
The Karnataka Bank Limited Creation Date: 20 Jul 1999 | ₹2.00 M | Open |
How Many Employees Work at Ewf Pharmaceuticals?
Unlock and access historical data on people associated with Ewf Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Ewf Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Ewf Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
